FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a…